Matching articles for "prevastatin"
Alirocumab (Praluent) to Lower LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • August 17, 2015; (Issue 1475)
The FDA has approved the subcutaneously injected
PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor alirocumab (Praluent – Sanofi/Regeneron)
as an adjunct to diet and maximally...
The FDA has approved the subcutaneously injected
PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor alirocumab (Praluent – Sanofi/Regeneron)
as an adjunct to diet and maximally tolerated
statin therapy for adults with heterozygous familial
hypercholesterolemia (HeFH) or clinical atherosclerotic
cardiovascular disease who require additional lowering
of LDL-cholesterol (LDL-C). It was not approved for
general use in statin-intolerant patients. Alirocumab
is the first PCSK9 inhibitor to be approved in the US.
Evolocumab (Repatha – Amgen), another PCSK9
inhibitor, was recently approved in Europe and has been
recommended for approval for the same indications in
the US by an FDA Advisory Committee.